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188A Randomized Trial of Fixed-Dose Combination
Brinzolamide 1%/Brimonidine 0.2% as
Adjunctive Therapy to Travoprost 0.004%ROBERT M. FELDMAN, GREGORY KATZ, MATTHEW MCMENEMY, DOUGLAS A. HUBATSCH, AND
TONY REALINI PURPOSE: To evaluate the safety and efficacy of adding
fixed-combination brinzolamide 1%/brimonidine 0.2%
(BBFC) as adjunctive therapy to travoprost 0.004%
(TRAV) in patients with open-angle glaucoma or ocular
hypertension.
 DESIGN: Multicenter, randomized, double-masked,
parallel-group phase 4 clinical trial.
 METHODS: SETTING: Multicenter; 32 sites in the
United States. PATIENT POPULATION: Total of 233 patients
with open-angle glaucoma or ocular hypertension and
with mean intraocular pressure (IOP) ‡21 mm Hg and
<32 mm Hg while receiving once-daily TRAV mono-
therapy. INTERVENTION:Masked BBFC or vehicle (3 times
daily) adjunctive to TRAV for 6 weeks. MAIN OUTCOME
MEASURE: Mean diurnal IOP averaged over 8 AM, 10
AM, 3 PM, and 5 PM time points at week 6. Superiority
of BBFCDTRAV over vehicleDTRAV was based on
statistical significance of a treatment difference favoring
BBFCDTRAV.
 RESULTS: Mean diurnal IOP at week 6 (least squares
mean ± standard error) was 17.6 ± 0.4 mm Hg and
20.7 ± 0.4 mm Hg in the BBFCDTRAV and vehi-
cleDTRAV groups, respectively (between-group
difference,L3.2 ± 0.5 mmHg; P< .0001). Superiority
of BBFCDTRAV over vehicleDTRAVwas established.
Mean and percent diurnal IOP change from baseline were
significantly greater with BBFCDTRAV compared with
vehicleDTRAV (P < .0001 for both). Conjunctival
hyperemia was the most common treatment-related
adverse event in either group (BBFCDTRAV, 12.8%;
vehicleDTRAV, 6.0%).
 CONCLUSIONS: Adjunctive treatment with BBFC
added to TRAV resulted in lower mean diurnal IOP after
6 weeks of treatment compared with vehicle added toupplemental Material available at AJO.com.
r publication Feb 21, 2016.
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G
LAUCOMA IS A PROGRESSIVE OPTIC NEUROPATHY
characterized by degeneration of retinal ganglion
cells that results in loss of visual field and, poten-
tially, leads to blindness.1 Although multiple factors (eg,
elevated intraocular pressure [IOP], family history,
ethnicity, corneal biomechanics) have been associated
with the development and progression of primary open-
angle glaucoma,2,3 large-scale clinical studies have demon-
strated that reducing IOP decreases the risk of progression
or conversion of ocular hypertension to glaucoma.4–7
Many patients require multiple IOP-lowering agents to
achieve and maintain their target IOP. In the Ocular
Hypertension Treatment Study, approximately 40% of
patients required >_2 medications to meet their target
IOPs.5 Initial therapy has been reported to be insufficient
in the first 2 years of treatment for 50% of patients in the
United States.8
Combination therapies are often effective when taken as
prescribed, but treatment adherence can decline with
increasing numbers of individual medications and
increasing treatment regimen complexity.9,10 Fixed-
combination medications allow concomitant administra-
tion of multiple ocular hypotensive medications with a
single-drop instillation, with the potential of additive
IOP-lowering efficacy and a simplified dosing regimen.11
A fixed combination recently approved by the US Food
and Drug Administration (FDA) is Simbrinza, which con-
tains the carbonic anhydrase inhibitor brinzolamide 1%
and the a2-adrengeric agonist brimonidine 0.2% (BBFC;
SIMBRINZA; Alcon Laboratories, Inc, FortWorth, Texas,
USA). Currently, BBFC is the only available FDA-
approved fixed-combination glaucoma medication that
does not contain a b-blocker. Two Phase 3 trials have
demonstrated superior IOP-lowering efficacy of BBFC
compared with its individual components (ie, brinzolamide
1% or brimonidine 0.2%).12,130002-9394
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Treatment guidelines for glaucoma have suggested a
stepwise approach to adding agents for patients with insuf-
ficient IOP control.14,15 However, adding a fixed-
combination therapy to monotherapy may be reasonable
in patients needing to reach a target IOP lower than may
be reasonably expected with addition of a single agent.
Additive efficacy of BBFC adjunctive to branded prosta-
glandin analogues was recently described (unpublished
data; Fechtner RD, et al. American Glaucoma Society,
2015). The purpose of this study was to evaluate the safety
and efficacy of adding BBFC as adjunctive therapy to the
prostaglandin analogue travoprost 0.004% (TRAV) in
patients with open-angle glaucoma or ocular hypertension.METHODS
 STUDY DESIGN AND TREATMENT: This was a prospec-
tive, multicenter, 1:1 randomized, double-masked,
parallel-group phase 4 clinical trial conducted at 32 sites
in the United States between October 2013 and April
2014 (ClinicalTrials.gov identifier, NCT01937299; regis-
tered September 2013). The study was performed in
compliance with the ethical principles of the Declaration
of Helsinki, Good Clinical Practice, and the Health Insur-
ance Portability and Accountability Act. The study proto-
col and consent forms were prospectively approved by The
University of Texas Health Science Center Houston Com-
mittee for the Protection of Human Subjects, Chesapeake
Institutional Review Board (IRB), West Virginia Univer-
sity IRB, and Sterling IRB. Informed consent was obtained
from patients at enrollment.
Eligible patients were aged >_18 years, were diagnosed
with primary or secondary open-angle glaucoma or ocular
hypertension, and had mean IOP >_21 mm Hg and
<32 mm Hg in at least 1 eye (the same eye[s]) at the
8 AM time point of both eligibility visits (ie, after washout
of prior IOP-lowering medications and while receiving
TRAV monotherapy). Exclusion criteria are provided in
the Supplementary Table (available at AJO.com).
The study consisted of 2 sequential phases: an open-label
run-in phase and a randomized, double-masked treatment
phase (Figure 1). The open-label phase included a
screening visit during which patients discontinued their
prior IOP-lowering medication(s) and simultaneously initi-
ated once-daily TRAV (TRAVATAN Z; Alcon Labora-
tories, Inc). TRAV therapy was continued throughout
the duration of the study, and at no point during the study
were patients without ocular hypotensive treatment. Eligi-
bility visits were scheduled after the appropriate washout
durations required based on patients’ prior ocular hypoten-
sive therapies. Informed consent was obtained at the
screening visit. After washout, eligibility IOP assessments
were conducted at 8 AM, 10 AM, 3 PM, and 5 PM (all
630 minutes), with the 2 visits scheduled 3–8 days apartVOL. 165 BRINZOLAMIDE/BRIMONIDINE Ato determine patients’ TRAV-treated baseline diurnal
IOP and IOP at individual time points.
Patients who met eligibility criteria at both visits were
randomized 1:1 to receive either BBFCþTRAV or vehi-
cleþTRAV for the 6-week duration of the randomized,
double-masked treatment phase. Randomization was
centralized and blocked and was conducted using an elec-
tronic data collection system with interactive response
technology. The random allocation sequence was gener-
ated using SAS 9.1 PROC PLAN software (SAS Institute,
Inc., Cary, NC). Patients, investigators, investigational
center staff, the study sponsor, and clinical monitors were
masked to treatment assignments. Assigned treatments
were provided in kits containing identical masked bottles,
labels, and packaging.
Randomized patients were instructed to instill 1 drop of
their masked treatment (BBFC or vehicle) in both eyes
3 times daily at approximately 8 AM, 3 PM, and 10 PM
and to instill 1 drop of TRAV in both eyes once daily at
bedtime. The treatment phase included 2 on-therapy
follow-up visits conducted at week 2 and week 6. The
schedule of study assessments is described in Table 1.
 EFFICACYOUTCOMES: The primary efficacy endpointwas
mean diurnal IOP averaged over 4 time points (8 AM, 10
AM, 3 PM, and 5 PM) at week 6. Secondary efficacy end-
points were mean diurnal IOP change and percent diurnal
IOP change from baseline at week 6. Additional outcomes
were mean diurnal IOP at week 2, mean and percent IOP
change from baseline at week 2, IOP at each time point at
week 2 and week 6, and mean and percent IOP change
from baseline at each time point at week 2 and week 6.
To limit potential bias, IOPwasmeasured using a masked
IOP reader, and study personnelwho administered eye drops
during study visits did not perform IOP measurements.
Intraocular pressure measurements were taken for both
eyes at all study visits using a calibration-verifiedGoldmann
applanation tonometer; 2 measurements were taken for
each eye at every time point. The same operator and reader
measured IOP for a given patient using the same method at
all visits. On study visit days, the 8 AM and 3 PM treatment
doses were administered by study personnel approximately
15 minutes after completion of IOP measurement.
Efficacy endpoints were analyzed in the intent-to-treat
data set (ie, all patients who received study medication
and completed at least 1 scheduled on-therapy visit).
Data from 1 eye from each patient (ie, the study eye)
were analyzed. If both eyes received study medication,
the eye with higher IOP at 8AMaveraged across the 2 eligi-
bility visits was selected. If IOP was equal between eyes at 8
AM assessments, the eye with higher IOP at 10 AM was
selected. If both eyes had equal IOP at both the 8 AM
and 10 AM time points, the right eye was selected as the
study eye. Baseline IOP at each time point was calculated
as the integer average of the IOP at the 2 eligibility visits
at that time point.189DJUNCTIVE TO TRAVOPROST
TABLE 1. Schedule of Assessments by Study Visit and Time Point for Patients With Open-Angle Glaucoma or Ocular Hypertension
Receiving Fixed-Combination Brinzolamide 1%/Brimonidine 0.2% or Vehicle Adjunctive to Travoprost 0.04%
Assessment Screen
Eligibility 1 and 2 Week 2 Week 6
8 AM 10 AM 3 PM 5 PM 8 AM 10 AM 3 PM 5 PM 8 AM 10 AM 3 PM 5 PM
Best-corrected visual acuity X X X X
Anterior segment examination X X X X
Intraocular pressurea X X X X X X X X X X X X X
Visual fields X X
Dilated eye examination X X
Adverse events X X X X X X X X X X X X X
aAt scheduled study visits, the 8 AM and 3 PM intraocular pressure measurements were performed before administration of the 8 AM and 3
PM doses of study treatments.
Open Label Run-in Phase 6-Week Randomized, Masked Treatment Phase 
Brinzolamide 1%/brimonidine 0.2% 
adjunctive to travoprost 0.004%
Vehicle adjunctive to travoprost 0.004%
Randomization Screening Washout Eligibility visit 1 
Eligibility 
visit 2 
2-week 
follow-up visit 
6-week 
follow-up visit 
(Scheduled 3–8 days apart) 
( 2 to 28 days) 
FIGURE 1. Study design schematic illustrating washout, randomization, and follow-up periods in patients with open-angle glaucoma
or ocular hypertension receiving fixed-combination brinzolamide 1%/brimonidine 0.2% or vehicle adjunctive to travoprost 0.004%.
The length of the washout period depended on the class of ocular hypotensive medication(s) used at screening. At washout, patients
simultaneously discontinued prior hypotensive therapies and initiated once-daily travoprost therapy. Time-matched intraocular pres-
sure measurements obtained at the 2 eligibility visits were averaged to yield travoprost-treated baseline intraocular pressure values. SAFETY OUTCOMES: Safety was evaluated from adverse
event (AE) reports and eye examination for all patients
exposed to treatment; safety outcomes were summarized
descriptively. Adverse events were coded using Medical
Dictionary for Regulatory Activities version 16.0 Preferred
Terms. Best-corrected visual acuity was assessed using a
standardized ETDRS chart and was calculated as the num-
ber of letters read correctly þ 30. Visual fields were evalu-
ated using achromatic automated perimetry and were
calculated as mean deviation from the Humphrey Field
Analyzer device. If both eyes were treated, visual fields
were averaged for the left and right eyes.
 STATISTICAL ANALYSIS: The primary efficacy endpoint
(mean diurnal IOP) was analyzed on an observed-case
basis; consequently, there was no imputation for missing
data. Treatment group differences in mean diurnal IOP at
week 6, mean diurnal IOP change from baseline at week
6, and percent diurnal IOP change from baseline at week
6 were determined based on least squares (LS) means using
a repeated-measures analysis of variance model that
accounted for covariate baseline IOP, with fixed effect
terms for treatment, visit, and treatment-by-visit interac-
tion. The superiority of BBFCþTRAV relative to vehi-
cleþTRAV was considered established if the mean190 AMERICAN JOURNAL OFreduction in diurnal IOP at week 6 was significantly greater
for the adjunctive therapy relative to monotherapy (ie,
lower mean diurnal IOP value with BBFCþTRAV), as
determined using a 2-sided statistical test at the 5% signif-
icance level. To ensure that the statistical model and asso-
ciated analyses were robust for any data points missing at
random, a sensitivity analysis was performed using the
last-observation-carried-forward (LOCF) method. In the
sensitivity analysis, time-matched data were imputed for
calculation and analysis of mean diurnal IOP at week 6.
A post hoc analysis with study site as a fixed effect in the
statistical model was conducted to confirm the results of
the preplanned primary endpoint analysis. There was no
preplanned statistical testing for treatment differences in
IOP data for supportive endpoints; however, these end-
points were also analyzed post hoc using a model analogous
to that described above. P values from this analysis were
generated for descriptive purposes only.
A sample size of approximately 200 patients was deter-
mined to be sufficient to detect a between-group difference
in mean diurnal IOP of 2.0 mm Hg, a common measure of
clinical significance in IOP studies, with >_90% power. This
estimate was based on an assumed IOP standard deviation
(SD) of 3.5–3.9 mmHg and a 2-sided t test at a significance
level of P < .05.MAY 2016OPHTHALMOLOGY
RESULTS
 PATIENTS: Of the 233 patients randomized to treatment,
229 were included in the intent-to-treat data set
(BBFCþTRAV, n ¼ 113; vehicleþTRAV, n ¼ 116;
Figure 2). Mean 6 SD patient age was 66.8 6 10.5 years;
most patients were female (59.4%; 136/229), white
(78.6%; 180/229) and were diagnosed with open-angle
glaucoma (72.1%; 165/229; Table 2). All demographic
characteristics were comparable between groups. Overall,
7.7% of randomized patients (18/233) discontinued the
study (BBFCþTRAV, 12.0%, 14/117; vehicleþTRAV,
3.4%, 4/116). The most common reason for discontinua-
tion was an AE (BBFCþTRAV, 11.1%, 13/117; vehicleþ-
TRAV, 0%). The remaining reasons for discontinuation
were lack of efficacy (vehicleþTRAV, 3.4%, 4/116) and
patient withdrawal (BBFCþTRAV, 0.9%, 1/117).
 EFFICACYOUTCOMES: Mean6 SD TRAV-treated base-
line IOP was 22.5 6 2.5 mm Hg in the BBFCþTRAV
group and 22.76 2.4 mm Hg in the vehicleþTRAV group
(Table 2). After 6 weeks of adjunctive therapy, LS mean
6 standard error diurnal IOP was 17.6 6 0.4 mm Hg for
patients receiving BBFCþTRAV compared with
20.7 6 0.4 mm Hg for patients receiving vehicleþTRAV
(between-group difference, 3.2 6 0.5 mm Hg; 95% con-
fidence interval, 4.2 to 2.2 mm Hg; P < .0001;
Figure 3). The criterion for superiority of BBFCþTRAV
was met. At week 6, the mean diurnal IOP change from
TRAV-treated baseline and the mean percent diurnal
IOP change from TRAV-treated baseline were signifi-
cantly greater with BBFCþTRAV compared with vehi-
cleþTRAV, and mean IOP at individual time points was
lower with BBFCþTRAV compared with vehicleþTRAV
(P< .0001; Table 3). At each time point (peak efficacy, 10
AM and 5 PM; trough efficacy, 8 AM and 3 PM) of the
week 2 and week 6 visits, mean IOP was lower, and mean
and mean percent IOP change from TRAV-treated base-
line were greater in the BBFCþTRAV group compared
with the vehicleþTRAV group (P < .0001; Table 4).
The largest IOP changes from baseline were observed in
patients receiving BBFCþTRAV at the 10 AM peak effi-
cacy time point. At the week 6, 10 AM time point, mean
6 SD IOP was lower with BBFCþTRAV compared with
vehicleþTRAV (16.7 6 3.3 mm Hg vs 20.5 6 4.3 mm
Hg). Mean IOP change from TRAV-treated baseline and
mean percent IOP change from TRAV-treated baseline
at the week 6, 10 AM time point were 6.2 6 3.3 mm
Hg and 26.7% 6 13.5% with BBFCþTRAV compared
with 2.2 6 3.8 mm Hg and 9.7% 6 16.2% with vehi-
cleþTRAV (Table 4).
The results of the LOCF sensitivity analysis and the post
hoc analysis with study site included in the statistical model
confirmed the results of the preplanned analysis.VOL. 165 BRINZOLAMIDE/BRIMONIDINE A SAFETY OUTCOMES: The mean 6 SD duration of expo-
sure to study medication was 39.2 6 10.2 days for patients
receiving BBFCþTRAV and 41.6 6 6.2 days for patients
receiving vehicleþTRAV. Adverse events were reported
for 37.6% of patients receiving BBFCþTRAV (44/117)
and 22.4% of patients receiving vehicle þTRAV (26/
116; Table 5). There were no serious AEs or deaths during
the study. Conjunctival hyperemia was the most frequently
reported treatment-related AE in either group
(BBFCþTRAV, 12.8%, 15/117; vehicleþTRAV, 6.0%,
7/116; Table 5). Other treatment-related AEs with an inci-
dence >5% in either group were dry mouth and blurred
vision. Twelve patients receiving BBFCþTRAV discon-
tinued the study because of 18 treatment-related AEs
(allergic conjunctivitis, 4 events; dizziness, dry mouth,
and eye irritation, 2 events each; asthenopia, conjunctival
hyperemia, eyelid erythema, feeling abnormal, insomnia,
nausea, rash, and somnolence, 1 event each). No patients
receiving vehicleþTRAV discontinued the study because
of a treatment-related AE. Most AEs were of mild severity,
and all were either mild or moderate. Overall, 88.0% of pa-
tients (103/117) tolerated (ie, did not discontinue)
BBFCþTRAV during the study.
BCVA was similar between groups and across all study
visits. Mean change from baseline to week 6 in both groups
was <2 ETDRS chart letters. No changes were detected in
visual fields between groups or between baseline and week 6
visits. In general, few changes in ocular signs from baseline
to week 6 were observed in either group for conjunctiva
(BBFCþTRAV, 10.3% [n ¼ 12]; vehicleþTRAV, 1.7%
[n ¼ 2]), eyelids (BBFCþTRAV, 3.4% [n ¼ 4]; vehicleþ-
TRAV, 0%), cornea (BBFCþTRAV, 1.7% [n ¼ 2]; vehi-
cleþTRAV, 0.9% [n ¼ 1]), or lens (BBFCþTRAV, 0%;
vehicleþTRAV, 0.9% [n ¼ 1]). The incidence of fundus
changes from baseline to week 6 was <1% in both groups.DISCUSSION
CONTROLOF IOP IS REQUIRED TO REDUCE THE RATEOF PRO-
gression of glaucoma; however, many patients require mul-
tiple IOP-lowering medications to achieve their target
IOP, and this can lead to cumbersome dosing regimens.
This study was conducted to evaluate the IOP-lowering ef-
ficacy and tolerability of BBFC added to TRAV compared
with vehicle added to TRAV.
After 6 weeks of treatment, statistically and clinically
relevant between-group differences in mean diurnal IOP
were evident; mean diurnal IOP was significantly lower
in patients receiving BBFCþTRAV compared with those
receiving vehicleþTRAV, and the criterion for superiority
of the adjunctive therapy was met. Clinically relevant IOP
reductions were observed after only 2 weeks of treatment.191DJUNCTIVE TO TRAVOPROST
Enrollment Assessed for eligibility (n=307)
Excluded (n=74)
Randomized (n=233)
Allocated to brinzolamide 1%/
brimonidine 0.2% + travoprost 0.004% 
(n=117)
Allocated to vehicle + 
travoprost 0.004% (n=116)
Analyzed (Intent to treat) (n=113)
Excluded from analysis (n=4)
• No on-therapy follow-up visits (n=4)
Completed the study (n=103)
Discontinued the study (n=14)
• Adverse event (n=13)
• Withdrawal by patient (n=1)
Analyzed (Intent to treat) (n=116)
Excluded from analysis (n=0)
Completed the study (n=112)
Discontinued the study (n=4)
• Lack of efficacy (n=4)
Allocation
Analysis
Follow-Up
FIGURE 2. Disposition of patients with open-angle glaucoma or ocular hypertension receiving fixed-combination brinzolamide 1%/
brimonidine 0.2% or vehicle adjunctive to travoprost 0.004%.Compared with vehicleþTRAV, diurnal IOP reductions
from TRAV-treated baseline were significantly greater in
the BBFCþTRAV group; additionally, IOP with
BBFCþTRAV was lower at all week 2 and week 6 time
points compared with vehicleþTRAV. Conjunctival
hyperemia was the most common AE observed in both
groups, and most treatment-related AEs were local ocular
side effects. Other safety parameters were generally un-
changed from baseline to week 6, and no new safety con-
cerns were identified for adjunctive therapy with
BBFCþTRAV beyond the known safety profiles of the in-
dividual medications.
The comparative efficacy of adjunctive therapy with
brinzolamideþ TRAV or brimonidineþTRAV compared
with TRAV monotherapy has been evaluated in several
prospective, randomized, masked studies of patients with
open-angle glaucoma or ocular hypertension.16–19 These
studies demonstrated that adjunctive therapy with either
brinzolamide or brimonidine was more efficacious than
TRAV alone. In a trial with similar design and treatment
duration compared with the current study, mean
diurnal IOP reductions from TRAV-treated baseline levels
were 2.8 mm Hg and 2.1 mm Hg with192 AMERICAN JOURNAL OFbrinzolamideþ TRAV and brimonidineþ TRAV, respec-
tively.17 Further, in an observer-masked, active controlled
crossover study of patients with open-angle glaucoma,
3 months of adjunctive therapy with fixed-combination
brimonidine/timolol or fixed-combination brinzolamide/
timolol added to TRAV produced mean diurnal IOP reduc-
tions of 10% and 14%, respectively, from the TRAV-
treated baseline of 20.1 mm Hg.20 Maximal IOP reduction
was observed at 10 AM in both groups; at this time point
mean IOP was reduced by approximately 3.9 mm Hg, or
18%, with both brimonidine/timololþTRAV and brinzola-
mide/timololþTRAV.20
In the current study, mean diurnal IOP with
BBFCþTRAVwas significantly lower than with vehicleþ-
TRAV, and BBFCþTRAV reduced the mean diurnal IOP
from TRAV-treated baseline (22.5 mm Hg) by 5.0 mm
Hg (21.9%); this was a significantly greater IOP reduc-
tion compared with the 2.0 mm Hg (8.8%) change
from baseline observed with vehicleþTRAV. The largest
IOP change from baseline at week 6 was observed at the
10 AM peak; mean IOP change from baseline
was 6.2 mm Hg (26.7%) in the BBFCþTRAV group
and 2.2 mm Hg (9.7%) in the vehicleþTRAV group.MAY 2016OPHTHALMOLOGY
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FIGURE 3. Mean diurnal intraocular pressure at week 6 in pa-
tients with open-angle glaucoma or ocular hypertension
receiving fixed-combination brinzolamide 1%/brimonidine
0.2% or vehicle adjunctive to travoprost 0.004% (intent-to-
treat population). Data reflect least squares mean ± standard er-
ror. Mean diurnal intraocular pressure is depicted within bars;
between-group difference is depicted above bars. Group sizes
reflect the number of patients who completed the study.
TABLE 2. Demographics and Baseline Characteristics of
PatientsWith Open-Angle Glaucoma or Ocular Hypertension
Randomized to Fixed-Combination Brinzolamide 1%/
Brimonidine 0.2% or Vehicle Adjunctive to Travoprost
0.004% (Intent-to-Treat Population)
Brinzolamide 1%/
Brimonidine 0.2% þ
Travoprost 0.004%
(n ¼ 113)
Vehicle þ Travoprost
0.004% (n ¼ 116)
Age, y
Mean 6 standard
deviation
67.5 6 10.3 66.0 6 10.6
Range 31–91 30–90
Age group, n (%)
<50 6 (5.3) 10 (8.6)
50–64 35 (31.0) 38 (32.8)
>_65 72 (63.7) 68 (58.6)
Sex, n (%)
Female 69 (61.1) 67 (57.8)
Male 44 (38.9) 49 (42.2)
Race, n (%)
White 91 (80.5) 89 (76.7)
Black or African
American
17 (15.0) 26 (22.4)
Asian 5 (4.4) 1 (0.9)
Ethnicity, n (%)
Not Hispanic or Latino 102 (90.3) 104 (89.7)
Hispanic or Latino 11 (9.7) 12 (10.3)
Diagnosis, n (%)
Open-angle glaucoma 81 (71.7) 84 (72.4)
Ocular hypertension 24 (21.2) 28 (24.1)
Open-angle glaucoma
with
pseudoexfoliation
6 (5.3) 2 (1.7)
Open-angle glaucoma
with pigment
dispersion
2 (1.8) 2 (1.7)
Diurnal intraocular
pressure, mm Hg
Mean 6 standard
deviation
22.5 6 2.5 22.7 6 2.4
Range 17.8–30.8 18.0–30.5The results of the current study indicate that adjunctive
therapy with BBFCþTRAV is more effective than vehi-
cleþTRAV and, when compared with the literature,
suggest that BBFC may be more effective than adjunctive
therapy with brinzolamide or brimonidine added individu-
ally, or brinzolamide/timolol or brimonidine/timolol added
as a fixed combination, to TRAV. Differences in study
design, patient population, and IOP assessment time points
make direct comparisons with the current results tenuous.
The findings of the current study are also similar to the
results of a 6-week randomized, parallel-group, double-
masked study comparing BBFC adjunctive to a once-
daily prostaglandin analogue (bimatoprost, latanoprost, orVOL. 165 BRINZOLAMIDE/BRIMONIDINE ATRAV) in patients with open-angle glaucoma or ocular
hypertension. At week 6, mean diurnal IOP in patients
receiving BBFC þ prostaglandin analogue was reduced
from baseline levels (on prostaglandin analogue therapy)
by 5.7 mm Hg (25%); the treatment difference between
BBFC þ prostaglandin analogue and vehicle þ prosta-
glandin analogue was 3.4 mm Hg in favor of the adjunc-
tive therapy (unpublished data; Fechtner RD, et al.
American Glaucoma Society, 2015).
A specific margin for superiority of BBFCþTRAV over
vehicleþTRAV was not defined in this study; rather, the
study was powered to detect a 2 mm Hg treatment differ-
ence, and superiority was concluded from a statistically sig-
nificant between-group difference in mean diurnal IOP
that favored BBFC. The outcome of this analysis favored
BBFCþTRAV, with a treatment difference of 3.16 mm
Hg vs vehicle. The magnitude of effect exceeded treatment
differences observed in previous superiority studies, which
have generally ranged from 0.8 mm Hg to 3.0 mm Hg
(P < .05 to P < .0001).12,13,21,22 Treatment differences
>1 mm Hg are often considered clinically relevant, as
indicated by the Early Manifest Glaucoma Trial that
demonstrated for every 1 mm Hg decrease in mean IOP,
the risk of progression decreased by approximately 10%.23
Further, the superiority outcome was of sufficient magni-
tude to minimize the likelihood that this result could be
attributed to equipment error or sensitivity limitations.193DJUNCTIVE TO TRAVOPROST
TABLE 4.Descriptive Statistics for Intraocular Pressure by Study Visit and TimePoint in PatientsWithOpen-Angle Glaucoma or Ocular
Hypertension Receiving Fixed-Combination Brinzolamide 1%/Brimonidine 0.2% or Vehicle Adjunctive to Travoprost 0.004% (Intent-
to-Treat Population)
Brinzolamide 1%/Brimonidine 0.2% þ Travoprost 0.004% Vehicle þ Travoprost 0.004%
n
Mean Intraocular
Pressure, mm Hg
Change From Baseline
n
Mean Intraocular
Pressure, mm Hg
Change From Baseline
Mean Percent Mean Percent
Travoprost monotherapy
Baseline
8 AM 113 24.2 6 2.3 - - 116 24.2 6 2.4 - -
10 AM 113 22.8 6 2.9 - - 116 22.8 6 2.8 - -
3 PM 113 21.5 6 3.0 - - 116 21.9 6 3.0 - -
5 PM 113 21.3 6 3.0 - - 116 21.6 6 3.0 - -
Mean diurnal 113 22.5 6 2.5 - - 116 22.7 6 2.4 - -
Adjunctive therapy
Week 2
8 AM 112 19.5 6 3.5 4.7 6 3.2 19.1 6 12.9 115 21.6 6 4.7a 2.6 6 3.7a 10.9 6 14.4a
10 AM 107 16.5 6 3.6 6.3 6 3.2 27.6 6 13.3 114 20.2 6 3.7a 2.4 6 3.5a 10.3 6 14.9a
3 PM 108 17.5 6 3.1 4.0 6 2.9 18.1 6 12.5 113 19.6 6 3.8a 2.3 6 3.5a 9.9 6 15.0a
5 PM 107 15.3 6 3.3 6.0 6 3.3 27.8 6 13.7 112 19.7 6 3.7a 1.8 6 3.3a 7.7 6 14.5a
Mean diurnal 113 17.4 6 3.0 5.1 6 2.7 22.5 6 11.3 115 20.5 6 4.4a 2.1 6 3.4a 9.2 6 13.6a
Week 6
8 AM 103 19.7 6 3.7 4.6 6 3.5 18.7 6 13.7 112 21.6 6 4.4a 2.5 6 3.4a 10.6 6 14.3a
10 AM 103 16.7 6 3.3 6.2 6 3.3 26.7 6 13.5 112 20.5 6 4.3a 2.2 6 3.8a 9.7 6 16.2a
3 PM 103 17.6 6 3.2 3.9 6 3.1 17.5 6 13.5 112 19.4 6 3.8a 2.4 6 3.3a 10.6 6 14.7a
5 PM 103 15.7 6 3.4 5.7 6 3.3 26.2 6 14.2 112 19.8 6 4.0a 1.7 6 3.6a 7.3 6 16.4a
Mean diurnal 103 17.4 6 2.8 5.1 6 2.6 22.3 6 10.8 112 20.3 6 3.7a 2.2 6 2.9a 9.6 6 12.9a
Data reflect descriptive mean 6 standard deviation.
aP< .0001 vs brinzolamide 1%/brimonidine 0.2%þ travoprost 0.004% from repeated-measures analysis of variance model that accounted
for covariate baseline intraocular pressure with fixed effect terms for treatment, visit, and treatment-by-visit interaction compound symmetry
covariance matrix; and Kenward-Roger method for denominator degrees of freedom.
TABLE 3. Descriptive Statistics for Between-Group Difference in Mean Intraocular Pressure and Mean Diurnal Intraocular Pressure
Change FromTravoprost-Treated Baseline atWeek 6 in PatientsWith Open-Angle Glaucoma or Ocular Hypertension Receiving Fixed-
Combination Brinzolamide 1%/Brimonidine 0.2% or Vehicle Adjunctive to Travoprost 0.004% (Intent-to-Treat Population)
Brinzolamide 1%/Brimonidine
0.2% þ Travoprost
0.004% (n ¼ 103)
Vehicle þ Travoprost
0.004% (n ¼ 112)
Between-Group
Difference
95% Confidence
Interval P Valuea
Mean intraocular pressure, mm Hg
8 AM 19.7 6 0.4 22.0 6 0.4 2.3 6 0.5 3.3 to 1.2 <.0001
10 AM 16.7 6 0.4 20.8 6 0.4 4.1 6 0.5 5.2 to 3.1 <.0001
3 PM 17.6 6 0.4 19.7 6 0.4 2.1 6 0.5 3.2 to 1.1 <.0001
5 PM 15.7 6 0.4 20.1 6 0.4 4.4 6 0.5 5.5 to 3.4 <.0001
Diurnal intraocular pressure
Mean change from travoprost
004%–treated baseline, mm Hg
5.0 6 0.3 2.0 6 0.3 3.0 6 0.4 3.8 to 2.2 <.0001
Mean percent change from travoprost
004%–treated baseline
21.9 6 1.2 8.8 6 1.2 13.0 6 1.7 16.4 to 9.7 <.0001
Data reflect least squares mean 6 standard error.
aP values were generated using repeated-measures analysis of variance models that accounted for covariate baseline intraocular pressure
with fixed effect terms for treatment, visit, and treatment-by-visit interaction; compound symmetry covariance matrix; and Kenward-Roger
method for denominator degrees of freedom.
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TABLE 5. Summary of Treatment-Emergent Adverse Events
in Patients With Open-Angle Glaucoma Receiving Fixed-
Combination Brinzolamide 1%/Brimonidine 0.2% or Vehicle
Adjunctive to Travoprost 0.004%
Adverse Event Category, n (%)
Brinzolamide 1%/
Brimonidine 0.2% þ
Travoprost 0.004%
(n ¼ 117)
Vehicle þ Travoprost
0.004% (n ¼ 116)
Frequency of adverse
events
44 (37.6) 26 (22.4)
Serious adverse
events
0 0
Treatment-related
adverse events
36 (30.8) 17 (14.7)
Discontinuations
because of an
adverse event
13 (11.1) 0
Treatment related 12 (10.3) 0
Not treatment related 1 (0.8) 0
Treatment-emergent
adverse eventsa
Conjunctival
hyperemia
16 (13.7) 7 (6.0)
Dry mouth 9 (7.7) 2 (1.7)
Blurred vision 7 (6.0) 5 (4.3)
Allergic conjunctivitis 5 (4.3) 0
Eye irritation 5 (4.3) 3 (2.6)
Dysgeusia 5 (4.3) 0
Eye pain 4 (3.4) 4 (3.4)
Corneal vital staining 4 (3.4) 0
Pruritus 3 (2.6) 1 (0.9)
Photophobia 3 (2.6) 0
Treatment-related
adverse eventsb
Conjunctival
hyperemia
15 (12.8) 7 (6.0)
Dry mouth 9 (7.7) 2 (1.7)
Blurred vision 7 (6.0) 5 (4.3)
Allergic conjunctivitis 5 (4.3) 0
Eye irritation 5 (4.3) 3 (2.6)
Dysgeusia 5 (4.3) 0
Eye pain 4 (3.4) 2 (1.7)
Corneal vital staining 4 (3.4) 0
Pruritus 3 (2.6) 1 (0.9)
Photophobia 3 (2.6) 0
Ocular hyperemia 2 (1.7) 0
Foreign body
sensation
2 (1.7) 0
Increased lacrimation 2 (1.7) 0
Dry eye 2 (1.7) 0
Eyelid erythema 2 (1.7) 0
Dizziness 2 (1.7) 0
Somnolence 2 (1.7) 0
aAdverse events with an incidence >_2% are presented.
bTreatment-related adverse events with an incidence >_1% are
presented.
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in the current study was both statistically significant and
clinically meaningful.
As expected, in the current study, the rates of treatment-
related AEs were greater with BBFCþTRAV than with
vehicleþTRAV, likely because patients in the adjunctive
therapy group were receiving 3 active medications
compared with only 1 in the vehicle-control group. The
conjunctival hyperemia rate with TRAV (6.0%) was
similar to previous reports (6.4%).24 Treatment-related
conjunctival hyperemia has been reported in 0.5%–2.7%
of patients receiving BBFC25,26; the higher rate of
treatment-related hyperemia observed with BBFCþTRAV
(12.8%) in the current study may reflect an additive effect
of combining BBFC and TRAV. Common treatment-
related AEs with BBFCþTRAV were consistent with the
known safety profiles of brinzolamide, brimonidine,
BBFC, and TRAV, and no new safety concerns specific
to adding BBFC adjunctive to TRAV were identified.
More patients in the BBFCþTRAV group discontinued
because of treatment-related AEs; however, no serious
AEs were reported, and approximately 90% of patients
tolerated the addition of BBFC to TRAV.
The lack of late afternoon and nighttime IOP assessment
time points is a limitation of this study. Twenty-four-hour
IOP fluctuation patterns can vary from individual to
individual.27 Further, brimonidine treatment can result in
large IOP fluctuations over a 24-hour period.20,28
Potential IOP fluctuations between the 5 PM and 8 AM
IOP assessments were not evaluated in this study. As
such, the additive efficacy of BBFCþTRAV with regard
to mean 24-hour IOP may be less than the daytime IOP-
lowering efficacy observed in this study. Additionally,
TRAV treatment was initiated at screening, where appro-
priate, at the same time that patients discontinued any
other prior IOP-lowering medications and was maintained
throughout the study. This ensured that patients were not
subjected to complete washout of all IOP-lowering medica-
tions at any point during the study, and therefore, compar-
ison of IOP lowering with BBFCþTRAV vs untreated
baseline was not possible. The short follow-up duration is
another limitation. Because local allergic side effects asso-
ciated with brimonidine may not be evident until after
several months of treatment, the rate of ocular AEs that
may occur with chronic BBFCþTRAV treatment may be
higher than was observed in this 6-week study. Identifica-
tion of potential AEs associated with long-term adjunctive
treatment with BBFCþTRAV may also require a longer
follow-up duration. Lastly, this study only evaluated the
addition of BBFC to TRAV; further study is needed to
generalize the results to the addition of BBFC to other pros-
taglandin analogues.
In conclusion, adding BBFC adjunctively to TRAV
resulted in lower mean diurnal IOP after 6 weeks of195DJUNCTIVE TO TRAVOPROST
treatment compared with vehicle added to TRAV; this dif-
ference was both statistically and clinically significant.
BBFCþTRAV was effective and well tolerated. By
combining 3-times-daily BBFC with a once-daily prosta-
glandin analogue, patients were able to administer 3 ocular
hypotensive agents with only 2 medication bottles and a196 AMERICAN JOURNAL OFsimplified dosing regimen compared with concomitant
use of the individual agents. For patients with open-angle
glaucoma or ocular hypertension already on a prosta-
glandin analogue and requiring additional IOP-lowering
therapy, BBFC is an efficacious option with no unexpected
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